Swedish Orphan Biovitrum AB (publ)
BIOVFOTCHealthcare● Active
$47.35
$-0.13(-0.26%)
Market Cap$16.4B
P/E Ratio—
52W High$48
52W Low$27.06
Swedish Orphan Biovitrum AB (publ)（BIOVF）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · BIOVF · 截至 2026-06-09
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $28.17B | $26.03B | $22.12B | $18.79B | $15.53B |
| Cost of Revenue | $15.88B | $5.79B | $5.00B | $4.78B | $3.48B |
| Gross Profit | $12.29B | $20.24B | $17.13B | $14.01B | $12.04B |
| Gross Margin %(computed) | 43.63% | 77.77% | 77.42% | 74.58% | 77.56% |
| Operating Expenses | |||||
| R&D Expenses | $3.24B | $3.54B | $2.80B | $2.35B | $1.99B |
| G&A Expenses | $11.14B | $7.55B | $10.16B | $7.85B | $6.29B |
| Total Operating Expenses | $4.26B | $14.62B | $13.06B | $10.17B | $8.26B |
| Operating Income | $8.03B | $5.63B | $4.07B | $3.81B | $3.73B |
| Operating Margin %(computed) | 28.50% | 21.61% | 18.38% | 20.29% | 24.04% |
| Interest Income | $0.00B | $0.03B | $0.03B | $0.01B | $0.42B |
| Interest Expense | $0.83B | $1.24B | $1.11B | $0.46B | $0.00B |
| Income Before Tax | $0.03B | $4.41B | $2.95B | $3.32B | $3.29B |
| Income Tax Expense | ($0.44B) | $0.53B | $0.55B | $0.68B | $0.62B |
| Net Income | $0.48B | $3.88B | $2.41B | $2.64B | $2.68B |
| Net Margin %(computed) | 1.69% | 14.93% | 10.89% | 14.04% | 17.25% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $1.39 | $11.37 | $7.39 | $8.52 | $8.67 |
| Wtd Avg Shares | 0.34B | 0.34B | 0.33B | 0.31B | 0.31B |
| EBITDA | $10.94B | $9.30B | $7.23B | $6.05B | $5.72B |
| EBITDA Margin %(computed) | 38.82% | 35.75% | 32.70% | 32.20% | 36.83% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-09 · SEK · B
深入了解Swedish Orphan Biovitrum AB (publ)
关于Swedish Orphan Biovitrum AB (publ)（BIOVF）损益表
Swedish Orphan Biovitrum AB (publ)（BIOVF）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，BIOVF实现营收$28.17B，毛利润$12.29B（毛利率43.63%），净利润$0.48B（净利率1.69%）。
常见问题
BIOVF · 4 问Swedish Orphan Biovitrum AB (publ)（BIOVF）2025财年营收为$28.17B，同比up8.2%。
BIOVF revenueBIOVF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09